Classes Get Cert., Lose State Law Claims In Opana MDL
By Lauraann Wood (June 4, 2021, 10:31 PM EDT) -- An Illinois federal judge on Friday certified two classes of painkiller Opana ER purchasers in multidistrict litigation over a pay-for-delay scheme Endo Pharmaceuticals allegedly entered to keep a generic version off the shelves, but he nixed the state law claims from their case.
U.S. District Judge Harry Leinenweber granted class status to a group of "end payor" plaintiffs in the MDL who bought or reimbursed at least a portion of the branded or generic versions of Opana ER, as well as a class of purchasers who bought either version of the drug directly from any manufacturer. The classes claim Endo overcharged...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!